Because individual responses to KD can vary, personalized guidance from healthcare providers is important to ensure safety and effectiveness
We are advancing this compound into Phase III development, CEO Brian Lian said in a statement, noting that Viking has received written feedback from an FDA Type C meeting and is currently preparing for an end of Phase II meeting with the agency, which we expect to occur later this year. Final Phase III plans, including design and timeline, will be disclosed after the meeting
The cost of a new vial is far less than the risk of injecting contaminated product
[DOI] [PMC free article] [PubMed] [Google Scholar] Rajan 2002 Rajan S, Wallace JI, Beresford SA, Brodkin KI, Allen RA, Stabler SP
It is the ultimate detox and antidote to toxins
No notable impact on blood glucose, cholesterol, or blood pressure has been observed in shortterm studies (glucose tolerance findings)